Unicycive Therapeutics, Inc. (UNCY)
NASDAQ
Healthcare
Biotechnology
$5.36
▼ -6.46%
Market Cap
$115.2M
Sector
Healthcare
Industry
Biotechnology
Beta
1.79
52-Wk Range
3.71-8.74
CEO
Shalabh K. Gupta
Country
US
Currency
USD
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Open full interactive analysis & DCF →